Received Oct 31, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | UNK | — | IM |
Normally experiences a pretty bad reaction to the vaccine, usually being gone for 2 or 3 days with a high fever and chills; High fever; Chills; This spontaneous case was reported by a consumer and describes the occurrence of IMMUNISATION REACTION (Normally experiences a pretty bad reaction to the vaccine, usually being gone for 2 or 3 days with a high fever and chills), PYREXIA (High fever) and CHILLS (Chills) in a female patient of an unknown age who received SPIKEVAX NOS (SPIKEVAX NOS) for COVID-19 prophylaxis. No Medical History information was reported. On an unknown date, the patient received dose of SPIKEVAX NOS (SPIKEVAX NOS) (Intramuscular use) 1 dosage form. On an unknown date, the patient experienced IMMUNISATION REACTION (Normally experiences a pretty bad reaction to the vaccine, usually being gone for 2 or 3 days with a high fever and chills), PYREXIA (High fever) and CHILLS (Chills). At the time of the report, IMMUNISATION REACTION (Normally experiences a pretty bad reaction to the vaccine, usually being gone for 2 or 3 days with a high fever and chills), PYREXIA (High fever) and CHILLS (Chills) had resolved. The action taken with SPIKEVAX NOS (SPIKEVAX NOS) (Intramuscular use) was unknown. Concomitant medication use information was not provided by reporter. The patient had always taken Moderna for every single dose and booster since it was released. And she normally experienced a pretty bad reaction to the vaccine, usually being gone for 2 or 3 days with a high fever and chills with vaccine. The patient wanted to take the Moderna vaccine. The doctor had given a prescription for the mNEXSPIKE vaccine. The question was about the difference between mNEXSPIKE and Spikevax. The reporter wondered if mNEXSPIKE would have fewer side effects, as the reporter just wanted to know the advantages because the doctor prescribed mNEXSPIKE 2025-2026, but the pharmacy only carried Spikevax 2025-2026. The reporter asked which dose was recommended between the 25mcg and the 50mcg and if there was only one dose available for mNEXSPIKE. Additionally, the reporter inquired whether the studies showed that mNEXSPIKE had fewer side effects than Spikevax. Lastly, the reporter asked why Moderna developed mNEXSPIKE and what advantages it had over Spikevax. It was unknown if the patient experienced any additional symptoms/events. Treatment medication use information was not provided by reporter. This case was linked to MOD-2025-790562 (Patient Link).